BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2018

Feb 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2018-02-15

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-15	Common Stock	M	10000	$38.59	Acquired	236494	Direct
2018-02-15	Common Stock	S	10000	$84.6285	Disposed	226494	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-15	Stock Option (Right to buy Common Stock)	$38.59	M	10000	Disposed	2018-05-21	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	182201	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on November 14, 2017.

F2: The price in column 4 is the weighted average price. The price actually received ranged from $84.095 to $84.98. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F3: Amount of securities beneficially owned has been updated from the reporting person's prior report to include 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.

F4: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 600 shares reported in the Form 4 Amendment filed with the S.E.C. on 01/02/2018.

F5: Reflects the number of stock options outstanding after the transaction from this specific stock option grant.